Heart FailureBETTER CARE-HFNCT06457152
Multi-Center Project: Building Electronic Tools To Enhance and Reinforce CArdiovascular REcommendations - Heart Failure
A study testing EHR-Emedded Alert in people with Heart Failure, run by NYU Langone Health at 4 sites in United States.
Trial summary
This study will test an automated, electronic health record (EHR-)embedded alert to improve prescribing of guideline-directed medical therapy for patients with heart failure and reduced ejection fraction (HFrEF). Read more about this study
- Who is it for?
- Ages 18 to 90 years
- Conditions the study is for
- Heart Failure
- What is being tested?
- EHR-Emedded Alert
- Could I receive a placebo?
- No, everyone receives an active treatment
- How many people
- 1,136 participants
- Where
- 4 sitesUnited States
- Study dates
- 4 Apr 2025to 29 Mar 2026
- Phase
- Interventional
- Are there results?
- None posted in the registry
Key requirements
Who can take part, as listed by the sponsor. Only the study team can confirm whether you are eligible, so take this list to your doctor.
- Ages 18 to 90 years
- All sexes
- No healthy volunteers
- Adult, Older adult
Who may be able to join
- Patient with an encounter visit at participating cardiology practice during the study period
- Patient with EF of less than or equal to 40% on most recent echocardiogram at the time of visit
- Patient ages 18-90
Who cannot join
- Pregnancy
- Ventricular assist device
- Hospice
- Cardiac amyloid
- Medication-specific exclusion for MRA: most recent systolic blood pressure less than 105 mm Hg, most recent potassium < 5.1, any potassium > 5.5, most recent glomerular filtration rate < 30 (using MDRD equation), or a documented MRA allergy.
Trial locations and contacts
4 sites in 1 country.
United States4 sites
University of Massachusetts
Boston, Massachusetts, 01003
OhioHealth
Columbus, Ohio, 43228
NYU Langone Health
New York, New York, 10016
University of Pennsylvania
Philadelphia, Pennsylvania, 19104
About this study
Official title: Multi-Center Project: BETTER CARE - HF (Building Electronic Tools To Enhance and Reinforce CArdiovascular REcommendations - Heart Failure)
This study will test an automated, electronic health record (EHR-)embedded alert to improve prescribing of guideline-directed medical therapy for patients with heart failure and reduced ejection fraction (HFrEF). The investigators have previously tested and implemented this alert at NYU Langone Health (NYULH), and will now test and implement this alert across three other health systems.
- Conditions
- Heart Failure
- Being tested
- EHR-Emedded Alert
- Medical subject headings
- Heart Failure
What participants receive
What participants receive. In a randomised study each person is assigned to one group by chance.
EHR-Emedded AlertOther
For patients randomized to the intervention group, an automated, EHR-embedded alert will be visible in the patient's chart that promotes appropriate medical therapy for patients with HFrEF.
| Study group | Role | What they receive |
|---|---|---|
| Intervention | Experimental | Participants who are randomized to receive the intervention (i.e., displaying the automated EHR-embedded alert). Receives: Other: EHR-Emedded Alert |
| Standard of Care | No intervention | Participants who are randomized to the control group (i.e., not displaying the automated EHR-embedded alert). |
What is being measured
The primary outcome is the main question the study is designed to answer.
Number of Patients with a Prescription for Mineralocorticoid Antagonists (MRA)
Measured at the prescription encounter level using patient EHR data.
Measured: Up to Day 30
Secondary outcomes (6)
Number of Patients with a Prescription for Beta-Blocker (BB)
Measured at the prescription encounter level using patient EHR data.
Measured: Up to Day 30
Number of Patients with a Prescription for ACE-I/ARB/ARNI
Prescription for angiotensin converting enzyme-inhibitors/angiotensin receptor blockers/angiotensin receptor neprilysin inhibitors (ACE-I/ARB/ARNI) measured at the prescription encounter level using patient EHR data.
Measured: Up to Month 36
Number of Patients with a Prescription for Sodium-Glucose Cotransporter-2 Inhibitor (SGLT2i)
Measured at the prescription encounter level using patient EHR data.
Measured: Up to Month 36
Number of Patients with Hyperkalemia
Measured using patient EHR data.
Measured: Up to Month 36
Number of Patients who are Hospitalized
Measured using patient EHR data.
Measured: Up to Month 36
Number of Patients who are Hospitalized for Heart Failure (HF)
Measured using patient EHR data.
Measured: Up to Month 36
Timeline
From the start of the study to its completion; the mark is today. Estimated dates are the sponsor’s plan.
- First posted13 Jun 2024
- Study start4 Apr 2025
- Primary completion4 Dec 2025
- Study completion29 Mar 2026
Resources
- Official record on ClinicalTrials.govThe registry entry this page is built from, with its full change history.
- Other trials for Heart FailureStudies of the same condition, open and under way.
- More trials run by NYU Langone HealthThe sponsor's other registered studies.
- What the trial phases meanHow a treatment moves from first tests in people to approval.
More details
For doctors and researchers: how the study is designed, who runs it, and its registry IDs.
Study design
- Study type
- Interventional
- Phase
- Phase N/A
- Primary purpose
- Health services research
- Allocation
- Randomised
- Intervention model
- Parallel groups
- Masking
- None (open label)
- Enrolment
- 1,136 participants (actual)
Sponsor and investigators
- Lead sponsor
- NYU Langone Health
- Sponsor type
- University, hospital or other
- Collaborators
- Massachusetts General Hospital, University of Pennsylvania, OhioHealth
- Responsible party
- Sponsor
- Investigators
- Amrita Mukhopadhyay, Principal investigator, NYU Langone Health
IDs, dates and publications
- ClinicalTrials.gov ID
- NCT06457152
- Sponsor's protocol ID
- 24-00179
- Acronym
- BETTER CARE-HF
- Status last verified
- Aug 2026
- First submitted
- 10 Jun 2024
- Last updated
- 17 Aug 2026
- Results posted
- No
- Data monitoring committee
- No
- FDA-regulated drug
- No
- FDA-regulated device
- No
- Individual data sharing
- Yes: The de-identified participant data from the final research dataset used in the published manuscript will be shared upon reasonable request beginning 9 months and ending 36 months following article publication or as required by a condition of awards and agreements supporting the research provided the investigator who proposes to use the data executes a data use agreement with NYU Langone Health. Requests may be directed to: amrita.mukhopadhyay@nyulangone.org. The protocol and statistical analysis plan will be made available on Clinicaltrials.gov only as required by federal regulation or as a condition of awards and agreements supporting the research.
Study at a glance
From the registry record, last updated by the sponsor on 17 Aug 2026. Recruitment status is as the sponsor reported it: confirm with the study team.
- Official title
- Multi-Center Project: BETTER CARE - HF (Building Electronic Tools To Enhance and Reinforce CArdiovascular REcommendations - Heart Failure)
- ClinicalTrials.gov ID
- NCT06457152
- Acronym / sponsor ID
- BETTER CARE-HF / 24-00179
- Conditions
- Heart Failure
- Study type
- Interventional
- Recruitment status
- Completed
- Enrolment
- 1,136 participants (actual)
- Lead sponsor
- NYU Langone HealthUniversity, hospital or other
- Collaborators
- Massachusetts General Hospital, University of Pennsylvania, OhioHealth
- Study start
- 4 Apr 2025 (actual)
- Primary completion
- 4 Dec 2025 (actual)
- Study completion
- 29 Mar 2026 (actual)
- First posted
- 13 Jun 2024 (actual)
- Results
- Not posted in the source record
Clinical summary
The research question as the sponsor registered it. This describes what the study plans to test, not what it found.
This study will test an automated, electronic health record (EHR-)embedded alert to improve prescribing of guideline-directed medical therapy for patients with heart failure and reduced ejection fraction (HFrEF). The investigators have previously tested and implemented this alert at NYU Langone Health (NYULH), and will now test and implement this alert across three other health systems.
Study design
- Primary purpose
- Health services research
- Allocation
- Randomised
- Intervention model
- Parallel groups
- Masking
- None (open label)
- Number of arms
- 2
| Arm | Type | Receives |
|---|---|---|
| Intervention | Experimental | Other: EHR-Emedded AlertParticipants who are randomized to receive the intervention (i.e., displaying the automated EHR-embedded alert). |
| Standard of Care | No intervention | –Participants who are randomized to the control group (i.e., not displaying the automated EHR-embedded alert). |
Who may qualify
- Ages
- 18 to 90 years
- Sex
- All
- Healthy volunteers
- Not accepted
- Age groups
- Adult, Older adult
Key inclusion criteria (3 listed)
- Patient with an encounter visit at participating cardiology practice during the study period
- Patient with EF of less than or equal to 40% on most recent echocardiogram at the time of visit
- Patient ages 18-90
Key exclusion criteria (5 listed)
- Pregnancy
- Ventricular assist device
- Hospice
- Cardiac amyloid
- Medication-specific exclusion for MRA: most recent systolic blood pressure less than 105 mm Hg, most recent potassium < 5.1, any potassium > 5.5, most recent glomerular filtration rate < 30 (using MDRD equation), or a documented MRA allergy.
Eligibility is decided by the study team after screening; this overview does not establish that a patient qualifies. Full inclusion and exclusion criteria.
Interventions
| Intervention | Type | Arms |
|---|---|---|
| EHR-Emedded AlertFor patients randomized to the intervention group, an automated, EHR-embedded alert will be visible in the patient's chart that promotes appropriate medical therapy for patients with HFrEF. | Other | Intervention |
Primary outcome
Number of Patients with a Prescription for Mineralocorticoid Antagonists (MRA)
Time frame: Up to Day 30
Measured at the prescription encounter level using patient EHR data.
6 secondary outcomes
Number of Patients with a Prescription for Beta-Blocker (BB)
Time frame: Up to Day 30
Number of Patients with a Prescription for ACE-I/ARB/ARNI
Time frame: Up to Month 36
Number of Patients with a Prescription for Sodium-Glucose Cotransporter-2 Inhibitor (SGLT2i)
Time frame: Up to Month 36
Number of Patients with Hyperkalemia
Time frame: Up to Month 36
Number of Patients who are Hospitalized
Time frame: Up to Month 36
Number of Patients who are Hospitalized for Heart Failure (HF)
Time frame: Up to Month 36
Results and safety
The study is completed, but results are not available in the source record. That does not mean the treatment did or did not work.
Research links
- Official record on ClinicalTrials.govLast updated by the sponsor 17 Aug 2026.
- Individual participant dataSharing planned: Yes. The de-identified participant data from the final research dataset used in the published manuscript will be shared upon reasonable request beginning 9 months and ending 36 months following article publication or as required by a condition of awards and agreements supporting the research provided the investigator who proposes to use the data executes a data use agreement with NYU Langone Health. Requests may be directed to: amrita.mukhopadhyay@nyulangone.org. The protocol and statistical analysis plan will be made available on Clinicaltrials.gov only as required by federal regulation or as a condition of awards and agreements supporting the research.
Related trials for Heart Failure
Recruiting
Using Ultromics EchoGo HFpEF Algorithm to Identify and Treat High Heart Failure Risk in Patients With Type 2 Diabetes
Heart Failure, Diabetes
RecruitingObservational study
dPmax for Predicting Right Ventricular Failure After Left Ventricular Assist Device Implantation
Ventricular Dysfunction, Right
Active, not recruiting
Comparison of the Balloon-Expandable Edwards Valve and Self-Expandable CoreValve Evolut R or Evolut PRO System for the Treatment of Small, Severely Dysfunctional Surgical Aortic Bioprotheses. The 'LYTEN' Trial
Aortic Valve Stenosis, Regurgitation, Aortic
RecruitingObservational study
Norepinephrine in the Management of General Anesthesia-Induced Arterial Hypotension in Chronic Heart Failure Patients
Hypotension
Enrolling by invitationObservational study
Multi-Scale Analysis of Phenotypes in Heart Failure (MAP-HEART)
Heart Failure
Referral and contact
AzTrials does not enrol participants or take referrals. Contact the study team or a site listed below; they decide who can take part. This study is not recruiting at the moment.
Amrita Mukhopadhyay principal investigator
NYU Langone Health
4 sites in 1 country: see every site and its status.
Questions about this trial
What is this clinical trial studying?
A study testing EHR-Emedded Alert in people with Heart Failure, run by NYU Langone Health at 4 sites in United States.
The full registered description is in the About this study section and the official record.
Who may be eligible to take part?
The sponsor lists 3 inclusion and 5 exclusion criteria. Eligibility is decided by the study team after screening, so read the full criteria and contact a listed site.
Is this clinical trial currently recruiting?
The record says: finished, as of the sponsor's last update on 17 Aug 2026. Status can change between updates, so confirm with the study contact before making plans.
Where is the study taking place?
The record lists 4 sites in United States. Whether a site is taking part right now should be confirmed with that site. See every site.
What are the possible benefits and risks?
They depend on the study and the treatment, and no study can promise a benefit. The study team explains the known risks during informed consent, before anyone joins; the record itself does not list them.
Are results available for this study?
The study is completed, but results are not available in the source record. That does not mean the treatment did or did not work.
How can a doctor refer a patient or contact the research team?
The record lists no contact. The official record names the sponsor, who can be asked directly. AzTrials does not enrol participants or take referrals.
What does the primary outcome measure?
Number of Patients with a Prescription for Mineralocorticoid Antagonists (MRA) (time frame: Up to Day 30). It is what the study was designed to measure, not a finding.
Where can I read the original study information?
Does a listing mean the treatment is approved or proven to work?
No. A listing means the study is registered. It does not show that the treatment is safe, works, or is approved by a regulator.
How often is this information updated?
AzTrials copies changed records from ClinicalTrials.gov every night and reloads the whole registry every week. The sponsor last updated this record on 17 Aug 2026.